ADVERTISEMENT

David A. Sallman

Magrolimab in Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes: 5F9005 Phase 1b Study Results

Introduction:

Deepa Jeyakumar ;

Eunice S. Wang ;

Joshua F. Zeidner ;

David A. Sallman ;

Daniel A. Pollyea , MD, MS;

Guillermo Garcia-Manero , MD;

Naval G. Daver ;

Joseph G. Jurcic ;

Suman N. Kambhampati ;

Monzr M. Al Malki ;

Tiffany N. Tanaka ;

Terrence J. Bradley ;

11/04/2022

Tolerability and Efficacy of the First-in-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia: Phase 1b Results

Introduction:

Joshua F. Zeidner ;

Suman N. Kambhampati ;

David A. Sallman ;

Monzr M. Al Malki ;

Richard Larson ;

Gabriel Mannis ;

Wanxing Chai-Ho ;

Tiffany N. Tanaka ;

Terrence J. Bradley ;

Deepa Jeyakumar ;

Eunice S. Wang ;

Giri Ramsingh ;

Camille Renard ;

Naval G. Daver ;

11/04/2022

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia

Introduction:

Naval G. Daver ;

Giri Ramsingh ;

Camille Renard ;

David A. Sallman ;

Andrew H. Wei ;

11/04/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

November 6 ⁠–⁠ November 8

NEI Congress

November 7 ⁠–⁠ November 10

WoundCon

November 8

November 8 ⁠–⁠ November 10

Dermatology Week

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Advertisement

Advertisement